Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.
Transcript
What role does adjuvant treatment play in the treatment of HER2-positive breast cancer?
I think the landscape in the adjuvant setting has also changed. Typically, the way we had previously approached patients with HER2-positive disease had been to either give a regimen called AC chemotherapy, followed by a taxane and Herceptin, or we would give a non-anthracycline-based therapy, which we call TCH, so using a docetaxel with carboplatin and trastuzumab. But, now we’ve seen introduction of a few new HER2 agents into the early-stage setting, one being pertuzumab.
So, there’s the APHINITY data that came out last year that showed that when you add pertuzumab to standard chemotherapy with trastuzumab, it resulted in an improvement in disease-free survival. That being said, that improvement was pretty small and seemed to be greater in patients who had higher risk disease. So, patients, for example, who had either node-positive disease or hormone-receptor-negative disease. So, at this point in time, we are, generally, incorporating pertuzumab into patients who have higher risk for HER2- positive disease.
One other agent we’re also including is neratinib, and this is a potent tyrosine kinase inhibitor against HER1, HER2, and HER4. This agent was studied in the exteNET trial, which looked at patients who had completed a year of trastuzumab based therapy, and then they got randomized to get a year of neratinib or nothing. They found that getting a year of neratinib, after completion of your year of trastuzumab, did provide additional benefit, but the benefit was really seen in the hormone-receptor-positive patients.
So, we do think about using neratinib in someone who had a particularly high-risk ER-positive tumor. I will said, that being said, the patients that were enrolled onto exteNET were all pertuzumab naïve, and now that we’re starting to integrate pertuzumab into adjuvant therapy, we really don’t have data about what the benefits are for using neratinib in someone who’s had prior pertuzumab.
Are there any identified biomarkers that guide a treatment approach for these patients?
Not at this time. I wish, but there aren’t any defined biomarkers that can help us predict which patients are likely to benefit from which treatment. I think where it would be particularly beneficial to us would be in trying to decide which patients are going to benefit from pertuzumab because the absolute benefit was small, then, I think there’s likely to be greater benefit in patients who may have certain biological predisposition to getting benefit from pertuzumab. So, there is ongoing work trying to look at biomarker predictors from the affinity trial that we’re waiting.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More